Spinal Cord Injury Treatment Market to Reach USD 11.28 Billion by 2032, Driven by Technological Advancements

With a CAGR of 4.98%, the spinal cord injury treatment market is expanding due to innovative therapies, increased awareness, and rising incidence rates.

Spinal Cord Injury Treatment Market

AUSTIN, TX, UNITED STATES, January 31, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The global spinal cord injury treatment market, valued at USD 7.31 billion in 2023, is projected to reach USD 11.28 billion by 2032, growing at a CAGR of 4.98% from 2024 to 2032

Growth in the Spinal Cord Injury Treatment Market Driven by Innovation and Rising Incidence
The spinal cord injury (SCI) treatment business is experiencing significant growth as a result of increasing incidence rates, technological advances, and the expansion of therapeutic options. Every year, about 250,000 to 500,000 people worldwide suffer from spinal cord injuries primarily caused by motor vehicle accidents, falls, or sports injuries. This trend has led to an increased need for SCI healthcare services, especially for the elderly and high-risk populations. Key factors that aid the contribution of the market growth are neurostimulation devices, and regenerative and stem cell therapies that help restore their mobility and reduce the complication rate. Government-funded research, especially in Western countries like the U.S., improves innovation, while developments in customizable robotic exoskeletons expand therapeutic alternatives. However, high treatment costs and the lack of efficient alternatives in underdeveloped regions complicate the adoption of such tools, thus creating a great demand for economic innovation.

Get a Free Sample Report of Spinal Cord Injury Treatment Market @ https://www.snsinsider.com/sample-request/4598

Key Players in Spinal Cord Injury Treatment Market
- Medtronic - (SynchroMed II Infusion System, RestoreSensor Neurostimulator)
- Johnson & Johnson - (DePuy Synthes Spine, INHANCE Shoulder System)

- Abbott Laboratories - (Proclaim XR Neurostimulator System, BurstDR Stimulation Therapy)
- Pfizer -(Pregabalin for Neuropathic Pain, NeuroRehabilitation Support Programs)
- Eli Lilly - (Cymbalta for Pain Management, Trulicity Diabetes Support)
- Boston Scientific - (Spectra WaveWriter SCS System, Precision Plus SCS System)
- Stryker - (Spinal Cord Stimulators, Neurovascular Stents)
- Zimmer Biomet- (Mobi-C Cervical Disc, Comprehensive Spine System)
- Baxter International - (Tisseel Fibrin Sealant, Infusor Pain Management Pump)
- Astellas Pharma - (Gabapentin for Nerve Pain, Rehabilitative Medicine Research)
- Acorda Therapeutics - (Ampyra for Spinal Cord Injury, Myobloc for Muscle Spasticity)
- ReWalk Robotics - (ReWalk Personal 6.0 Exoskeleton, ReStore Soft Exosuit)
- Ekso Bionics - (EksoNR Neurorehabilitation Suit, EksoGT Exoskeleton)
- Sanofi - (Rilutek for Neurological Conditions, Multaq for Cardiac Health)
- Roche - (Ocrevus for Neurological Disorders, Rehabilitation R&D Programs)
- Novartis - (Gilenya for Spinal Cord Function, Zykadia for Symptom Relief)
- Merck & Co. - (Gabapentin for Neuropathic Pain, Pain Management Solutions)
- NeuroPace - (Responsive Neurostimulation System, VNS Therapy for Neuromodulation)
- Integra LifeSciences - (NeuraGen Nerve Guide, Camino ICP Monitor)
- Alnylam Pharmaceuticals - (Onpattro for Nerve Disorders, Lumasiran for Oxalate Reduction)

Segment Analysis

By Treatment Type

The surgery segment dominated the spinal cord injury (SCI) treatment market with a 41% market share due to its central role in stabilizing, preserving function, and treating the immediate consequences of spinal cord injuries. In severe cases of SCI, especially those with fractures, dislocations, or injury to the spinal column, surgery is often required. Surgical procedures, including decompression surgery, spinal fusion, and internal fixation, are required to prevent further injury, stabilize the spine, and improve recovery chances.

Additionally, advancements in surgical techniques such as minimally invasive procedures have improved outcomes for patients, thus contributing to the growth of the segment. The significant success rates and the potential for lasting improvements in mobility and quality of life for these patients mean that surgery is a key treatment option for patients suffering from SCI, further solidifying its position in the marketplace.

By Distribution Channel

In 2023, the hospital pharmacy segment dominated the spinal cord injury (SCI) treatment market, capturing a 47% market share. This dominance was developed because of the crucial purpose that the hospital pharmacy has in the supervision of medications from SCI patients, particularly the administration of advanced pharmaceuticals such as corticosteroids and analgesics. These drugs are essential in postinjury care, and the rising incidence of SCI increases the demand.

The retail Pharmacy segment is growing at the fastest rate as a greater number of consumers seek drugs and support services outside of the hospital. Prescription medications, such as painkillers and anti-inflammatory medications, are broadly needed in various medical fields, especially with the growing trend toward outpatient care and home therapy. Increasing awareness of the emerging concept of personalized medicine in recent years has led to an improved understanding among patients regarding the therapeutic options available for SCI. As a result, retail pharmacies are witnessing an increased demand for services, positioning them as potentially key players in the SCI treatment landscape.

Spinal Cord Injury Treatment Market Segmentation

By Treatment Type
• Corticosteroid
• Spinal Traction
• Surgery

By Injury
• Partial Spinal Cord Injury
• Complete Spinal Cord Injury

By End-User
• Trauma Centers
• Hospitals
• Others

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regional Analysis
North America dominated the market and accounted for around 39% market share in 2023. This dominance is due to newer treatment options like corticosteroids and spinal traction along with a considerably high incidence of SCIs. The U.S. is vital, with nearly 12,000 new SCI cases reported annually and a population of over a quarter million affected. Patients from all over the globe are treated in the leading diagnostic and rehabilitation centers, thus contributing highly toward regional market growth. The cost annually of overseeing SCI treatment in the U.S. is approximately USD 3 billion.

The fastest-growing market for SCI treatment is in the Asia-Pacific region. The rise is primarily due to an increase in road traffic accidents, an aging population, and improvements in healthcare facilities. Increasing awareness and focus on innovative therapeutic options will drive market growth in the region, making Asia-Pacific a leading player in the next few years.

Recent Developments

- April 2024 – Medtronic plc, a leading healthcare technology company, revealed that the U.S. Food and Drug Administration (FDA) has approved its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for managing chronic pain.
- May 2023 – Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for treating chronic back pain in individuals who have not undergone or are not eligible for back surgery.

Buy Full Research Report on Spinal Cord Injury Treatment Market 2024-2032 @
https://www.snsinsider.com/checkout/4598

Table of Contents – Major Key Points

Speak with Our Expert Analyst Today to Gain Deeper Insights @
https://www.snsinsider.com/request-analyst/4598

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Akash Anand
SNS Insider Pvt. Ltd

415-230-0044
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
